Pfizer (PFE +0.9%) looks to be fairly valued, says MKM Partners. The firm cut the shares to...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer (PFE +0.9%) looks to be fairly valued, says MKM Partners. The firm cut the shares to Neutral today, saying that it expects the drug giant to only launch three new products between 2013 and 2017, which is the lowest number and least relative revenue contribution of all its U.S. peers. The limited pipeline means significantly reduced news flow over the next few years, which also means fewer upside catalysts.